Shots:

• The two P-III studies (COUGH-1 & -2) involves assessing of gefapixant (45/15mg- bid) vs PBO in 2-044 patients with refractory or unexplained chronic cough for 12 & 24wks. respectively
• In both the studies- gefapixant (45 mg) resulted in reduction of objectively measured 24hrs.-cough frequency @12 & 24wks. (18.45% & 14.64%)- reduction in cough frequency (62% & 63%)- estimated relative reduction (17.68% & 15.79% )- 77.1% improvement in cough-related QoL respectively- presented at Virtual ERS International Congress 2020
• The gefapixant (15mg- bid) did not meet its 1EPs in either study. Gefapixant (PO) is a selective P2X3 receptor antagonist- for the potential treatment of refractory or unexplained chronic cough

­ Ref: Merck | Image: Merck